PP72 Demonstration of dose-dependent target inhibition using a quantitative biomarker assay for SB939, a potent, orally active HDAC inhibitor, in a Phase I clinical study in solid tumors

  • V. Novotny-Diermayr, A.-L. Liang, Y.K. Loh, H. Hentze, R. Jayaraman, K. Ethirajulu, J. Zhu, J.M. Wood
  • European Journal of Cancer Supplements, October 2009, Elsevier
  • DOI: 10.1016/s1359-6349(09)72194-9

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication


The following have contributed to this page: Dr veronica diermayr